Clinical Trials · NCT05548231
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 32
- Start date
- Oct 2022
- Locations
- 2 sites, China
- Primary endpoint
- Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration